JP2016526167A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526167A5
JP2016526167A5 JP2016517685A JP2016517685A JP2016526167A5 JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5 JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5
Authority
JP
Japan
Prior art keywords
peptides
sample
alzheimer
disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016517685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526167A (ja
Filing date
Publication date
Priority claimed from GBGB1310203.3A external-priority patent/GB201310203D0/en
Application filed filed Critical
Publication of JP2016526167A publication Critical patent/JP2016526167A/ja
Publication of JP2016526167A5 publication Critical patent/JP2016526167A5/ja
Ceased legal-status Critical Current

Links

JP2016517685A 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法 Ceased JP2016526167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310203.3 2013-06-07
GBGB1310203.3A GB201310203D0 (en) 2013-06-07 2013-06-07 Materials and methods relating to Alzheimer's disease
PCT/GB2014/051741 WO2014195715A1 (en) 2013-06-07 2014-06-05 Materials and methods relating to alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2016526167A JP2016526167A (ja) 2016-09-01
JP2016526167A5 true JP2016526167A5 (enExample) 2018-04-19

Family

ID=48875949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517685A Ceased JP2016526167A (ja) 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法

Country Status (6)

Country Link
US (1) US20160123997A1 (enExample)
EP (1) EP3004894A1 (enExample)
JP (1) JP2016526167A (enExample)
CA (1) CA2914559A1 (enExample)
GB (1) GB201310203D0 (enExample)
WO (1) WO2014195715A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
WO2019012671A1 (ja) * 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP7334781B2 (ja) * 2019-06-28 2023-08-29 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
WO2022102654A1 (ja) * 2020-11-10 2022-05-19 株式会社Mcbi バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法
US20240077501A1 (en) * 2020-12-28 2024-03-07 Mcbi Inc. Judgment supporting information generating method, judgment supporting information generating system, and information processing device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
CA2457695A1 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
US8232066B2 (en) * 2006-07-03 2012-07-31 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20100159486A1 (en) * 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
DK2389587T3 (en) * 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Similar Documents

Publication Publication Date Title
JP2016526167A5 (enExample)
Bahadır et al. Applications of electrochemical immunosensors for early clinical diagnostics
JP2016105097A5 (enExample)
JP2018500004A5 (enExample)
WO2007117444A3 (en) Protein detection by aptamers
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
JP2017524130A5 (enExample)
JP2016520192A5 (enExample)
JP2016511406A (ja) アルツハイマー病の診断のための方法と組成物
JP2016507233A5 (enExample)
JP2015530868A5 (enExample)
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
JP2017508144A5 (enExample)
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
BR112014018204A8 (pt) Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo
JP2017524933A5 (enExample)
HK1254818A1 (zh) 抗原肽及其用於诊断和治疗自闭症的用途
JP2014524583A5 (enExample)
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
MX2022000444A (es) Un biomarcador para la enfermedad de alzheimer utilizando muestras de sangre de sujetos con diagnostico clinico de la enfermedad de alzheimer.
JP2020530120A5 (enExample)
WO2012122094A3 (en) Biomarkers of cardiac ischemia
WO2014151079A3 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer
WO2016143805A1 (ja) 膀胱がんの検出方法
JP2017522890A5 (enExample)